Maxim Group set a $12.00 target price on Athersys, Inc. (NASDAQ:ATHX) in a report published on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on ATHX. Zacks Investment Research raised Athersys from a hold rating to a buy rating and set a $2.25 price target on the stock in a research note on Thursday, September 7th. ValuEngine cut Athersys from a hold rating to a sell rating in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Athersys currently has an average rating of Hold and an average target price of $7.17.

Athersys (NASDAQ ATHX) opened at $1.84 on Thursday. Athersys has a 12 month low of $1.02 and a 12 month high of $2.63.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/20/athersys-inc-athx-pt-set-at-12-00-by-maxim-group.html.

In other Athersys news, insider William Lehmann, Jr. sold 15,000 shares of Athersys stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $2.38, for a total transaction of $35,700.00. Following the transaction, the insider now owns 527,380 shares of the company’s stock, valued at approximately $1,255,164.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 9.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in shares of Athersys by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,800 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Athersys by 17.2% in the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 9,019 shares in the last quarter. Thompson Davis & CO. Inc. grew its stake in shares of Athersys by 743.9% in the 3rd quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 56,683 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Athersys by 329.7% in the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 56,345 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in shares of Athersys in the 2nd quarter valued at approximately $113,000. 19.94% of the stock is owned by institutional investors and hedge funds.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Stock Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related stocks with our FREE daily email newsletter.